Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Access Protocol for Patients Continuing SU011248 Treatment
2005-005335-94Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sunitinib in cancer, sponsored by Pfizer. Primary endpoints: Access to continued SU011248 treatment and Safety profile of SU011248. Started Feb 2006; status: terminated.
02
Drugs
sunitinib
03
Conditions
cancer
Beyond the preview
Go deeper on 2005-005335-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005335-94.